Create issue ticket

114 Possible Causes for Anti CD52, Antibody

Did you mean: Anti CD52, antimony

  • Prolymphocytic Leukemia

    After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m(2) weekly for 4 weeks, complete remission was obtained.[ncbi.nlm.nih.gov] The child died after 8 months despite aggressive chemotherapy, anti-CD52, and an allogeneic bone marrow transplant.[ncbi.nlm.nih.gov] Abstract Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant[ncbi.nlm.nih.gov]

  • T-Cell Prolymphocytic Leukemia

    Surface phenotype using monoclonal antibody was inadequate to predict T-cell function of the cells from this patient with T-PLL.[ncbi.nlm.nih.gov] PURPOSE: We conducted a retrospective analysis to evaluate the safety and efficacy of Campath-1H, an anti-CD52 humanized monoclonal antibody, in previously treated T-prolymphocytic[ncbi.nlm.nih.gov] Gov't MeSH terms Adult Aged Aged, 80 and over Alemtuzumab Antibodies, Monoclonal, Humanized/administration & dosage* Antibodies, Monoclonal, Humanized/adverse effects Antibodies[ncbi.nlm.nih.gov]

  • Daclizumab

    Gov't MeSH terms Antibodies, Monoclonal/chemistry* Antibodies, Monoclonal/therapeutic use Antibodies, Monoclonal, Humanized Basiliximab Binding Sites Complementarity Determining[ncbi.nlm.nih.gov] BACKGROUND: We performed a randomized trial evaluating alemtuzumab, a humanized anti-CD52 monoclonal antibody, in living donor (LD) kidney transplantation.[ncbi.nlm.nih.gov] […] maintenance immunosuppression) versus daclizumab in living donor renal transplantation. [2010.11] BACKGROUND: We performed a randomized trial evaluating alemtuzumab, a humanized anti-CD52[druglib.com]

  • Immune Hemolytic Anemia

    The causative antibodies were found to be a drug-independent IgM antibody in the serum and eluate that reacted only with E-positive RBC, although the patient's RBC were E-negative[ncbi.nlm.nih.gov] Rovelli et al 6 described a patient who failed to respond to rituximab and was subsequently treated with alemtuzumab (an anti-CD52 monoclonal antibody targeting all circulating[pediatrics.aappublications.org] CONCLUSIONS: This is the first reported case of IHA due to a cimetidine antibody where a drug-dependent antibody was demonstrated.[ncbi.nlm.nih.gov]

  • Neuromyelitis Optica

    Damage to astrocytes by anti-aquaporin-4 antibody (AQP4-Ab), also known as NMO antibody, has been implicated as the cause of neuromyelitis optica.[ncbi.nlm.nih.gov] Abstract Alemtuzumab is an anti-CD52 monoclonal antibody recently licensed for use in relapsing-remitting multiple sclerosis.[ncbi.nlm.nih.gov] (AQP4-Ab), also known as NMO antibody, has been implicated as the cause of neuromyelitis optica.[doi.org]

  • Autoimmune Hemolytic Anemia

    AIHA caused by warm autoantibodies (w-AIHA), ie, antibodies that react with their antigens on the red blood cell optimally at 37 C, is the most common type, comprising 70%[ncbi.nlm.nih.gov] Rovelli et al 6 described a patient who failed to respond to rituximab and was subsequently treated with alemtuzumab (an anti-CD52 monoclonal antibody targeting all circulating[pediatrics.aappublications.org] […] followed by granulocyte colony-stimulating factor was effective in achieving complete remission in 5 of 8 patients with highly refractory warm AIHA. 67 Alemtuzumab, a humanized anti-CD52[doi.org]

  • Paroxysmal Cold Hemoglobinuria

    The D-L antibody is classically a biphasic IgG anti-P autoantibody identified by the D-L test. Rare case reports confirm the existence of IgM D-L antibodies.[ncbi.nlm.nih.gov] […] followed by granulocyte colony-stimulating factor was effective in achieving complete remission in 5 of 8 patients with highly refractory warm AIHA. 67 Alemtuzumab, a humanized anti-CD52[haematologica.org] The autoantibody that causes this syndrome is called the Donath Landsteiner antibody.[clinlabnavigator.com]

  • Microscopic Polyangiitis

    Anti-neutrophil cytoplasmic antibodies (ANCA) appear to play an important role in the pathogenesis of ANCA-associated vasculitis (AAV).[ncbi.nlm.nih.gov] Lockwood CM, Hale G, Waldman H, Jayne DR (2003) Remission induction in Behcet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.[link.springer.com] Anti-neutrophil cytoplasmic antibody (ANCA) is associated with small-vessel vasculitis particularly in the kidneys and can induce the formation of neutrophil extracellular[ncbi.nlm.nih.gov]

  • Renal Vasculitis

    Abstract Few studies have reported on the long-term prognosis of anti-neutrophil cytoplasmic antibody (ANCA)-negative renal vasculitis.[ncbi.nlm.nih.gov] Other therapies including Mycophenolate mofetil (MMF), anti-TNF therapy, leflunomide, methotrexate, anti-CD52 therapy, B cell depletion therapy and intravenous immunoglobulin[bmcnephrol.biomedcentral.com] Abstract We report the first case of renal antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis treated with autologous mesenchymal stromal cells (MSCs).[ncbi.nlm.nih.gov]

  • Paraneoplastic Syndrome

    Bien , Conjoint occurrence of GABAB receptor antibodies in Lambert–Eaton myasthenic syndrome with antibodies to the voltage gated calcium channel , Journal of Neuroimmunology[doi.org] Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP (2001) Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative[doi.org] antibody.[clinlabnavigator.com]

Further symptoms